| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 888.00 | 13.6% | 23.2% |
| Total Income | 913.00 | 13.7% | 25.2% |
| Expenditure | 836.00 | 17.4% | 18.1% |
| PBT | 67.00 | 26.4% | 219.1% |
| Net Profit | 61.00 | 25.6% | 205.0% |
| OPM | 18.81% | 3.95pp | 32.96pp |
| NPM | 6.68% | 3.53pp | 3.94pp |
| EPS | 3.61 | 24.9% | 296.7% |
Wockhardt's Q3 FY26 Revenue Surges 22%, EBITDA Grows 72%
10 Feb 2026 · 10 Feb, 3:05 pm
Summary
Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 3‘ Quarter Results for Financial Year 2025-26, today. The company saw a revenue growth of 22% and EBITDA growth of 72% in Q3 FY 26 compared to the previous year.
Key Highlights
- 1
Revenue of Rs.888 crore in Q3FY26 compared to Rs.725 Cr in the previous year
- 2
EBITDA of Rs.173 Cr compared to Rs.100 Cr in the previous year
- 3
Profit before tax Rs.67 cr for Q3FY26 as compared to Rs.21 cr in the previous year
- 4
Biosimilar Business growing at 38% vs Q2FY26
- 5
India Branded Business stood at Rs.146 crore in Q3FY26 with a growth of 28% compared to the previous year
- 6
UK region stood at Rs.343 crore in Q3FY26 with a growth of 15% compared to the previous year
- 7
Emerging Markets region stood at Rs.264 crore in Q3FY26 with a growth of 48% compared to the previous year
- 8
Irish region stood at Rs.57 crore in Q3FY26 with a growth of 23% compared to the previous year
- 9
New Products Launch: 7 Filings and 17 launches in our International Business
- 10
Novel Antibiotics: Key Updates - ZAYNICH® and MIQNAF® NAFITHROMYCIN
Management Comments
Wockhardt Limited
The Company’s strength lies in its robust and end to end well integrated Biotech infrastructure. Looking ahead, the upcoming launch of Insulin analogs over the next few quarters represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.
Informational and educational content only. Not investment advice.